Correction of a pathogenic gene mutation in human embryos
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Genome editing has potential for the targeted correction of germline mutations. Here we describe the correction of the heterozygous MYBPC3 mutation in human preimplantation embryos with precise CRISPR-Cas9-based targeting accuracy and high homology-directed repair efficiency by activating an endogenous, germline-specific DNA repair response. Induced double-strand breaks (DSBs) at the mutant paternal allele were predominantly repaired using the homologous wild-type maternal gene instead of a synthetic DNA template. By modulating the cell cycle stage at which the DSB was induced, we were able to avoid mosaicism in cleaving embryos and achieve a high yield of homozygous embryos carrying the wild-type MYBPC3 gene without evidence of off-target mutations. The efficiency, accuracy and safety of the approach presented suggest that it has potential to be used for the correction of heritable mutations in human embryos by complementing preimplantation genetic diagnosis. However, much remains to be considered before clinical applications, including the reproducibility of the technique with other heterozygous mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Germline editing has been used for years in animals, including mice, rats, monkeys and many others, and experiments show that it can be done in both nonviable or viable human embryos as well 110-113 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [112]
In the citing paper
“Of the studies that have been conducted, the reported efficiencies of repair with templates in human embryos are very low (5,7,8).”
From Frequent loss of heterozygosity in CRISPR-Cas9–edited early human embryos (2021) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Orthwein, A. et al. Mitosis inhibits DNA double-strand break repair to guard against telomere fusions. Science 344, 189–193 (2014)”
Cited work 10.1126/science.1248024 · retracted 2025-01-09 · notice 10.1126/science.adv1263 · this paper published 2017-08
Citations
Cites
1 retracted
Mitosis Inhibits DNA Double-Strand Break Repair to Guard Against Telomere Fusions
Orthwein, A., Fradet-Turcotte, A., Noordermeer, S. M., Canny, M. D., Brun, C. M., Strecker, J., Escribano-Diaz, C., & Durocher, D. (2014) · Science · doi:10.1126/science.1248024 · Cited by 319
RetractedA Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationAntoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Cited by
Items 401–500 of 948
Germline Genome Editing Research: What Are Gamete Donors (Not) Informed About in Consent Forms?
Niemiec, E., & Howard, H. C. (2020) · The CRISPR Journal · doi:10.1089/crispr.2019.0043 · Cited by 15
“Consent to genomic sequencing Ma et al.(9) not only obtained gametes and blood/skin samples from some of the donors, but also generated large amounts of the donors’ genomic data through the whole”
BackgroundMethodInfluentialDance, A. (2017) · Nature Biotechnology · doi:10.1038/nbt.3998 · Cited by 19
Xue, Y., & Shang, L. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.939295 · Cited by 15
“This inevitably requires China to strike a balance between growing medical biotechnology and adhering to worldwide research norms in bioethics as well as controlling biosafety and biosecurity, especially after the “He Jiankui affair” and several other types of research (Liang et al., 2015; Ma et al., 2017; He, 2022).”
BackgroundHypertrophic cardiomyopathy in MYBPC3 carriers in aging
Ananthamohan, K., Stelzer, J. E., & Sadayappan, S. (2024) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2023.29 · Cited by 13
“CRISPR Cas-based gene modification is in the proof-of-concept stage for MYBPC3 mutations [259] .”
Li, Y., Weng, Y., Bai, D., Jia, Y., Liu, Y., Zhang, Y., Kou, X., Zhao, Y., Ruan, J., Chen, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18391-y · Cited by 16
Self-citationWong, P. K., Cheah, F., Syafruddin, S. E., Mohtar, M. A., Azmi, N., Ng, P. Y., & Chua, E. W. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.592571 · Cited by 17
Diversification of the CRISPR Toolbox: Applications of CRISPR-Cas Systems Beyond Genome Editing
Balderston, S., Clouse, G., Ripoll, J. J., Pratt, G. K., Gasiūnas, G., Bock, J.-O., Bennett, E., & Aran, K. (2021) · The CRISPR Journal · doi:10.1089/crispr.2020.0137 · Cited by 15
Stern, J. A., Rivas, V. N., Kaplan, J. L., Ueda, Y., Oldach, M. S., Ontiveros, E. S., Kooiker, K. B., van Dijk, S. J., & Harris, S. P. (2023) · Scientific Reports · doi:10.1038/s41598-023-36932-5 · Cited by 13
The Council of Europe and the prohibition on human germline genome editing
Baylis, F. E., & Ikemoto, L. C. (2017) · EMBO Reports · doi:10.15252/embr.201745343 · Cited by 13
Braun, M., & Dabrock, P. (2017) · EMBO Reports · doi:10.15252/embr.201745542 · Cited by 13
“But, even despite a broad consensus — backed by the Oviedo Convention as well as by nearly all scientific and political institutions — not to pass this line, this agreement has recently come under pressure in light of new developments [3] and institutional statements.”
Droplet based vitrification for cell aggregates: Numerical analysis
Shi, M., Feng, S., Zhang, X., Ji, C., Xu, F., & Lu, T. J. (2018) · Journal of the mechanical behavior of biomedical materials/Journal of mechanical behavior of biomedical materials · doi:10.1016/j.jmbbm.2018.03.026 · Cited by 15
Translating emerging molecular genetic insights into clinical practice in inherited cardiomyopathies
Asatryan, B., & Medeiros‐Domingo, A. (2018) · Journal of Molecular Medicine · doi:10.1007/s00109-018-1685-y · Cited by 12
Treatment of heritable diseases using CRISPR: Hopes, fears, and reality
Kofler, N. M., & Kraschel, K. L. (2018) · Seminars in Perinatology · doi:10.1053/j.semperi.2018.09.012 · Cited by 14
Cell and Gene Therapies for Mucopolysaccharidoses: Base Editing and Therapeutic Delivery to the CNS
Christensen, C. L., Ashmead, R. E., & Choy, F. Y. M. (2019) · Diseases · doi:10.3390/diseases7030047 · Cited by 16
“One such group used gold NPs to simultaneously bind and deliver Cas9 RNPs and donor DNA in mice resulted in HDR, a technique coined CRISPR-Gold [176].”
BackgroundInfluentialPristyazhnyuk, I. E., Minina, J. M., Korablev, A. N., Serova, I. A., Fishman, V., Gridina, M. M., Rozhdestvensky, T. S., Gubar, L., Skryabin, B. V., & Serov, O. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-50649-4 · Cited by 13
Hypertrophic Cardiomyopathy: Genetic Testing and Risk Stratification
Stafford, F., Thomson, K. L., Butters, A., & Ingles, J. (2021) · Current Cardiology Reports · doi:10.1007/s11886-020-01437-4 · Cited by 15
Expected advances in human fertility treatments and their likely translational consequences
Gleicher, N. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1525-4 · Cited by 16
“They attributed their technical progress primarily to concomitant intracytoplasmic sperm injection (ICSI) of oocytes and injections of Crispr-Cas9 [6].”
BackgroundInfluentialPharmacogenomics in cardiac therapy: Personalizing treatment for heart health
Naderi, N., Jolfayi, A. G., Azimi, A., Maleki, M., & Kalayinia, S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118392 · Cited by 16
The role of cardiac microenvironment in cardiovascular diseases: implications for therapy
Yao, J., Chen, Y., Huang, Y., Sun, X., & Shi, X. (2024) · Human Cell · doi:10.1007/s13577-024-01052-3 · Cited by 14
“Cas9 protein introduction can modify the fertilization of sperms with MYBPC3 mutation from HCM patients with oocytes from healthy donor [154].”
Han, Y., Fan, L. L., & Xue, Y. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.04.027 · Cited by 21
“In addition, Chinese researchers have repeatedly crossed “ red lines, ” triggering intense international controversies [21 – 23].”
BackgroundBanerjee, D., Bhattacharya, A., Puri, A. V., Munde, S. V., Mukerjee, N., Mohite, P. B., Kazmi, S. W., Sharma, A., Alqahtani, T., & Shmrany, H. A. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000002111 · Cited by 15
CRISPR-Cas9 Applications in Cardiovascular Disease
Khouzam, J. P., & Tivakaran, V. S. (2020) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2020.100652 · Cited by 13
Cardiomyocyte Dysfunction in Inherited Cardiomyopathies
Hassoun, R., Budde, H., Mügge, A., & Hamdani, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011154 · Cited by 16
Greenfield, A. (2018) · British Medical Bulletin · doi:10.1093/bmb/ldy020 · Cited by 14
Safety of Germline Genome Editing for Genetically Related “Future” Children as Perceived by Parents
Ishii, T., & Beriaín, Í. D. M. (2019) · The CRISPR Journal · doi:10.1089/crispr.2019.0010 · Cited by 18
Responsible Translational Pathways for Germline Gene Editing?
Cwik, B. (2020) · Current Stem Cell Reports · doi:10.1007/s40778-020-00179-x · Cited by 17
Making sense of heritable human genome editing: Scientific and ethical considerations
Greenfield, A. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.12.008 · Cited by 16
Genetics and Genomics Content in Nursing Education: A National Imperative
Connors, L. M., & Schorn, M. N. (2018) · Journal of Professional Nursing · doi:10.1016/j.profnurs.2018.06.003 · Cited by 14
What Do We Really Think About Human Germline Genome Editing, and What Does It Mean for Medicine?
Musunuru, K., Lagor, W. R., & Miano, J. M. (2017) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.117.001910 · Cited by 17
“A more recent report in August 2017 of GGE to correct a disease-causing gene mutation in viable human embryos that, in principle, could have been carried to term and resulted in healthy offspring was widely heralded in the press as a breakthrough and drew considerable attention.(1) What was”
A Practical Guide to Genome Editing Using Targeted Nuclease Technologies
Porter, S. N., Levine, R. M., & Pruett‐Miller, S. M. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180022 · Cited by 18
“In 2017, Ma et al. published their work demonstrating CRISPR-Cas-mediated gene correction of a heterozygous pathogenic mutation in viable, single-cell human embryos in vitro (262).”
The history, use, and challenges of therapeutic somatic cell and germline gene editing
Ryu, J., Adashi, E. Y., & Hennebold, J. D. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.02.040 · Cited by 13
Should we use CRISPR gene editing in human embryos?
Kubikova, N., Keefe, D. L., Wells, D., Oktay, K., & Feinberg, E. C. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.08.009 · Cited by 15
Briski, O., Motta, G. L., Ratner, L. D., Allegroni, F., Pillado, S., ÁLVAREZ, G., Gutierrez, B., Tarragona, L., Zaccagnini, A. S., Acerbo, M., et al. (2024) · Theriogenology · doi:10.1016/j.theriogenology.2024.02.028 · Cited by 15
Dicorato, M. M., Citarelli, G., Mangini, F., Alemanni, R., Albanese, M., Cicco, S., Greco, C. A., Forleo, C., Basile, P., Carella, M. C., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13051256 · Cited by 13
“The study demonstrated the remarkable capacity of CRISPR-Cas9 to produce a normal MYBPC3 allele in 72% of the embryos [52].”
At the heart of gene edits in human embryos
Winblad, N., & Lanner, F. (2017) · Nature · doi:10.1038/nature23533 · Cited by 13
Kumar, S., Yadav, N., Pandey, S., & Thelma, B. K. (2018) · Journal of Genetics · doi:10.1007/s12041-018-0953-5 · Cited by 11
Prat, F., Toutain, J., Boutin, J., Amintas, S., Cullot, G., Lalanne, M., Lamrissi‐Garcia, I., Moranvillier, I., Richard, E., Blouin, J., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.07.015 · Cited by 14
The non-coding genome in early human development – Recent advancements
Paloviita, P., & Vuoristo, S. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.02.010 · Cited by 13
Investigating pediatric disorders with induced pluripotent stem cells
Durbin, M. D., Cadar, A. G., Chun, Y. W., & Hong, C. C. (2018) · Pediatric Research · doi:10.1038/s41390-018-0064-2 · Cited by 13
“Human iPSCs were grown also on rat intestinal matrix, to engineer a humanized intestinal graft for nutrient absorption in patients with short bowel syndrome.(21) The established protocol for generating 3D cerebral organoids from iPSCs, replicates brain developmental stages.”
BackgroundNew Turns for High Efficiency Knock-In of Large DNA in Human Pluripotent Stem Cells
He, X., Li, Y., & Feng, B. (2018) · Stem Cells International · doi:10.1155/2018/9465028 · Cited by 13
Self-citationCarter, S. R., & Warner, C. M. (2018) · Health Security · doi:10.1089/hs.2018.0067 · Cited by 11
“141,142 Outside of China, genome editing techniques have been used in human embryos in the UK 143 and in the United States 144 (because federal funding for such efforts is pro-hibited in the US, this effort was funded privately).”
What to Expect When Expecting CRISPR Baby Number Four
Scott, C. T., & Selin, C. L. (2019) · The American Journal of Bioethics · doi:10.1080/15265161.2018.1562793 · Cited by 13
Designing Preclinical Studies in Germline Gene Editing: Scientific and Ethical Aspects
Nordgren, A. (2019) · Journal of Bioethical Inquiry · doi:10.1007/s11673-019-09947-9 · Cited by 15
An introduction to genome editing CRISPR-Cas systems
Singh, V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818140-9.00001-5 · Cited by 18
Harper, J. C., Aittomäki, K., Borry, P., Cornel, M. C., de Wert, G. M. W. R., Dondorp, W., Geraedts, J. P. M., Gianaroli, L., Ketterson, K., Liebaers, I., et al. (2017) · Human Reproduction Open · doi:10.1093/hropen/hox015 · Cited by 13
“As newer, more accurate, efficient, and therefore safer GGE systems are being developed, it is to be expected that these technical limitations could be overcome (Ishii, 2017) as was recently documented in the case of hypertrophic cardiomyopathy (Ma et al., 2017).”
BackgroundMiskel, D., Poirier, M., Beunink, L., Rings, F., Held-Hoelker, E., Tholen, E., Tesfaye, D., Schellander, K., Salilew‐Wondim, D., Blaschka, C., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-14699-5 · Cited by 14
Governance of Heritable Human Gene Editing World-Wide and Beyond
Xue, Y., & Shang, L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19116739 · Cited by 17
“For example, the accessibility of a powerful genetic engineering tool has already led to ethical challenges with Chinese scientist He Jiankui’s engineering of human embryonic genomes [29].”
BackgroundInfluentialUnveiling the Future of Cardiac Care: A Review of Gene Therapy in Cardiomyopathies
Venturiello, D., Tiberi, P. G., Perulli, F., Nardoianni, G., Guida, L., Barsali, C., Terrone, C., Cianca, A., Lustri, C., Sclafani, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313147 · Cited by 14
Query the merits of embryo editing for reproductive research now
Hyun, I., & Osborn, C. (2017) · Nature Biotechnology · doi:10.1038/nbt.4000 · Cited by 10
Herrera, R. J., & Garcia‐Bertrand, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-804124-6.00013-6 · Cited by 22
Yu, Z., Khan, A. R., Zia‐ul‐haq, H. M., Tian-shan, M., Tanveer, M., & Sharif, A. (2022) · Operations Management Research · doi:10.1007/s12063-022-00311-6 · Cited by 11
How Genome Editing could be used in the Treatment of Cardiovascular Diseases
Musunuru, K. (2018) · Personalized Medicine · doi:10.2217/pme-2017-0078 · Cited by 10
Canada's Assisted Human Reproduction Act: Pragmatic Reforms in Support of Research
Bubela, T. M., Kleiderman, E., Master, Z., Ogbogu, U., Ravitsky, V., Zarzeczny, A., & Knoppers, B. M. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00157 · Cited by 11
Lee, Y., & Kang, E. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.8.141 · Cited by 14
“Recently, DNA cutting techniques known as CRISPR/Cas9 (35), have been modified to edit genes in embryos directly.”
BackgroundInfluentialSelf-citationNanoparticle‐mediated genome editing in single‐cell embryos via peptide nucleic acids
Putman, R., Ricciardi, A. S., Carufe, K. E. W., Quijano, E., Bahal, R., Glazer, P. M., & Saltzman, W. M. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10458 · Cited by 9
“Using CRISPR co-injected with sperm, Ma et al.(4) were able to reduce mosaicism present in their edited human embryos.”
MethodRodiño‐Janeiro, B. K., Pardo‐Camacho, C., Santos, J., & Martínez, C. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00186.2018 · Cited by 12
“This approach is usually used to cure autosomal dominant mutations in human cells, embryos, or animal models (98, 132, 169) although its limited in some aspects as the low correlation between some gene expression changes in human comparing the same orthologs in mice (20).”
BackgroundKleiderman, E., & Stedman, I. (2019) · Journal of Community Genetics · doi:10.1007/s12687-019-00430-x · Cited by 13
Personalized precision medicine
Konieczny, L., & Roterman, I. (2019) · Bio-Algorithms and Med-Systems · doi:10.1515/bams-2019-0047 · Cited by 9
South Korea’s Institute for Basic Science faces review
Zastrow, M. (2020) · Nature · doi:10.1038/d41586-020-01465-8 · Cited by 11
CRISPR‐Cas Biochemistry and CRISPR‐Based Molecular Diagnostics
Weng, Z., You, Z., Yang, J., Mohammad, N., Lin, M., Wei, Q., Gao, X., & Zhang, Y. (2023) · Angewandte Chemie · doi:10.1002/ange.202214987 · Cited by 12
Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders
Wal, P., Aziz, N., Singh, C. P., Rasheed, A., Tyagi, L. K., Agrawal, A., & Wal, A. (2024) · Current Gene Therapy · doi:10.2174/0115665232268840231222035423 · Cited by 14
Machine Learning-Driven Prediction of CRISPR-Cas9 Off-Target Effects and Mechanistic Insights
Bhardwaj, A., Tomar, P., & Nain, V. (2024) · The EuroBiotech Journal · doi:10.2478/ebtj-2024-0020 · Cited by 15
Butt, H., Sathish, S., London, E., Johnson, T. L., Essawi, K., Leonard, A. K., Tisdale, J. F., & Demirci, S. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.047 · Cited by 14
Gw, E. (2017) · Journal of Genetic Disorders & Genetic Reports · doi:10.4172/2327-5790.1000164 · Cited by 9
“In principle this should be 100% successful, if the assumption that a particular single gene is responsible for a particular medical condition is accurate (for example ca 40% of patients with familial hypertrophic cardiomyopathy (HCM) have a mutation in the MYBPC3 gene on chromosome 11 [5]), and if the technique can b…”
BackgroundLala, I. (2019) · Journal of Religion and Health · doi:10.1007/s10943-019-00770-5 · Cited by 11
Emrani, J., Ahmed, M., Newman, R. H., Thomas, M. D., Mowa, C. N., & Teleha, J. C. (2020) · Journal of Chemical Education · doi:10.1021/acs.jchemed.9b01154 · Cited by 10
Translational Medicine: Towards Gene Therapy of Marfan Syndrome
Kallenbach, K., Remes, A. K., Müller, O. J., Arif, R., Zaradzki, M., & Wagner, A. H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11143934 · Cited by 9
“Thus, by generating the cellular repair machinery and replacing the mutated DNA sequence, CRISPR/Cas9 can be used to delete, replace, or add genetic sequences [65].”
MethodInfluentialSchmidt, J. K., Reynolds, M. R., Golos, T. G., & Slukvin, I. I. (2022) · Retrovirology · doi:10.1186/s12977-022-00604-5 · Cited by 10
“Microinjection of CRISPR/Cas9 constructs after fertilization at the onecell stage has been shown to result in mosaic editing [24, 28–30], whereas injections at the time of fertilization in human embryos have resulted in more uniform editing patterns when performing allele-specific targeting of the paternal allele [31,…”
BackgroundMechanisms of the Specificity of the CRISPR/Cas9 System in Genome Editing
Kulishova, L. M., Vokhtantsev, I. P., Kim, D. V., & Zharkov, D. O. (2023) · Molecular Biology · doi:10.1134/s0026893323020139 · Cited by 11
Self-citationBao, L., Hannon, C., Cruz-Migoni, A., Ptchelkine, D., Sun, M., Miller, A., Bunjobpol, W., Quevedo, C. E., Derveni, M., Chambers, J. S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16742-2 · Cited by 9
Duchenne muscular dystrophy: genome editing gives new hope for treatment
Crispi, V., & Matsakas, A. (2018) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2017-135377 · Cited by 11
Gene Editing of Human Embryos with CRISPR/Cas9: Great Promise Coupled with Important Caveats
Schenkwein, D., & Ylä‐Herttuala, S. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.007 · Cited by 13
“CRISPR/Cas9 techniques could become a reasonable and safe approach for clinical applications, the current study by Ma et al.(1) undoubtedly reports a step forward and opens theoretical possibilities to treat several human inborn errors and genetic mutations which otherwise cannot be cured with current medical practice…”
BackgroundMethodInfluentialAt the Heart of Genome Editing and Cardiovascular Diseases
Hernández‐Benítez, R., Martinez, L. M., Lajara, J., Magistretti, P. J., Montserrat, N., & Belmonte, J. C. I. (2018) · Circulation Research · doi:10.1161/circresaha.118.312676 · Cited by 9
“to correct a mutation in the MYBPC3 gene that is associated with hypertrophic cardiomyopathy.(4) Correction of the MYBPC3 gene in human embryos is an example of how these technologies can be used to prevent a variety of CV disorders originated from the inheritance of a single copy of a defective gene.”
BackgroundSelf-citationCzajka, M., Zajkowska, A., Gawlak, M., Bujalska‐Zadrożny, M., & Małecki, M. (2020) · Anticancer Research · doi:10.21873/anticanres.14448 · Cited by 9
Lavine, K. J., & Greenberg, M. J. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10021-5 · Cited by 9
CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals
Karapurkar, J. K., Antao, A. M., Kim, K.-S., & Ramakrishna, S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.018 · Cited by 14
Unmet Needs in the Treatment of Hypertrophic Cardiomyopathy
Hutt, E., Nissen, S. E., & Desai, M. Y. (2021) · Future Cardiology · doi:10.2217/fca-2020-0242 · Cited by 9
The worsening divergence of biotechnology: the importance of risk culture
Trump, B. D., Cummings, C. L., Loschin, N., Keisler, J. M., Wells, E., & Linkov, I. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1250298 · Cited by 14
CRISPR: Established Editor of Human Embryos?
Li, X., Tu, Z., Yang, W., & Li, S. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.08.007 · Cited by 10
“In this work (Ma et al., 2017), the authors examined 58 human embryos fertilized with sperm carrying the MYBPC3 mutation and found that 42 (72.4”
BackgroundMethodInfluentialA Preview of Selected Articles
Atkinson, S. P. (2017) · Stem Cells · doi:10.1002/stem.2745 · Cited by 9
Genome Editing Redefines Precision Medicine in the Cardiovascular Field
Dzilic, E., Lahm, H., Dreßen, M., Deutsch, M.-A., Lange, R., Wu, S. M., Krane, M., & Doppler, S. A. (2018) · Stem Cells International · doi:10.1155/2018/4136473 · Cited by 12
Yang, Y., & Huang, Y. (2019) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12061 · Cited by 8
ReGene: Blockchain backup of genome data and restoration of pre-engineered expressed phenotype
Dambrot, S. M. (2018) · IEEE Annual Ubiquitous Computing, Electronics & Mobile Communication Conference (UEMCON) · doi:10.1109/uemcon.2018.8796768 · Cited by 9
“In a recent groundbreaking but still-debated demonstration of gene editing’s preventative potential, an in vitro CRISPR– Cas9 procedure corrected a mutation that causes sudden death in young athletes [11].”
BackgroundPractical Approaches for Knock-Out Gene Editing in Pigs
Ratner, L. D., Motta, G. L., Briski, O., Salamone, D., & Fernández-Martín, R. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2020.617850 · Cited by 10
Regulating genetic engineering guided by human dignity, not genetic essentialism
Gregg, B. (2021) · Politics and the Life Sciences · doi:10.1017/pls.2021.29 · Cited by 11
“Engineering a particular trait in a human embryo does not necessarily lead to the trait’s expression (Ma et al., 2017).”
BackgroundIranpanah, A., Majnooni, M. B., Biganeh, H., Amirian, R., Rastegari‐Pouyani, M., Filosa, R., Cheang, W. S., Fakhri, S., & Khan, H. Z. (2024) · Phytotherapy Research · doi:10.1002/ptr.8228 · Cited by 10
“In line, mutations of the PI3K pathway have already been introduced as predictive biomarkers for the selection of a suitable therapy (Lui et al., 2013; Ma et al., 2017).”
Current progress in CRISPR-Cas systems for autoimmune diseases
Israr, J., & Kumar, A. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.07.011 · Cited by 11
Should Cognitive Differences Research Be Forbidden?
Meisenberg, G. (2019) · Psych · doi:10.3390/psych1010021 · Cited by 9
“In addition to embryo selection, knowledge of causal polymorphisms also allows for targeted genome editing to replace low-IQ alleles with high-IQ alleles and to repair genes that have been damaged by mutations [65].”
BackgroundEmerging and Enabling Technologies in Biodefense
Berger, K. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-03053-7_13 · Cited by 9
Mooney, M. R., Davis, E. E., & Katsanis, N. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00949 · Cited by 7
Emergent challenges for CRISPR: biosafety, biosecurity, patenting, and regulatory issues
Braddick, D., & Ramarohetra, R. F. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818140-9.00021-0 · Cited by 14
New perspectives in the pharmacological treatment of hypertrophic cardiomyopathy
Maltês, S., & Lopes, L. R. (2020) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2019.03.013 · Cited by 8
“MYBPC3 gene in stem cells and human embryos using CRISPR/Cas9.(66) In this study, the efficiency of genome editing was much higher in embryos than in stem cells.”
BackgroundMethodInfluentialGene conversion following CRISPR/Cas9 DNA cleavage: an overlooked effect
Burgio, G. (2020) · Gene Therapy · doi:10.1038/s41434-020-0154-8 · Cited by 10
“This observation confirms previous reports and might partly explain the presence of endogenous repair following gene editing in model organisms, human, and mouse embryos [3, 8, 9].”
ResultNovas perspetivas no tratamento farmacológico da miocardiopatia hipertrófica
Maltês, S., & Lopes, L. R. (2020) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2019.03.008 · Cited by 10
The evolution of our understanding of human development over the last 10 years
Brivanlou, A. H., & Gleicher, N. (2021) · Nature Communications · doi:10.1038/s41467-021-24793-3 · Cited by 9
Pradeep, R., Akram, A., Proute, M. C., Kothur, N., Georgiou, P., Serhiyenia, T., Shi, W., Kerolos, M. E., & Mostafa, J. A. (2021) · Cureus · doi:10.7759/cureus.17548 · Cited by 12
“Interestingly, there were no off-target events found [69].”
BackgroundFor the Good of the Globe: Moral Reasons for States to Mitigate Global Catastrophic Biological Risks
Johnson, T. (2024) · Journal of Bioethical Inquiry · doi:10.1007/s11673-024-10337-z · Cited by 9
“The same goes for knowledge surrounding the influence of particular human genes on our traits and how these might be used for personal gain (Ma, et al. 2017).”
Expanding the spectrum of CVD genetics
Schunkert, H. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.209 · Cited by 8
In Utero Gene Therapy and Genome Editing
Hartman, H. A., Rossidis, A. C., & Peranteau, W. H. (2018) · Current Stem Cell Reports · doi:10.1007/s40778-018-0117-9 · Cited by 16
Time Matters: Gene Editing at the Mouse 2-Cell Embryo Stage Boosts Knockin Efficiency
Reyes, Á. P., & Lanner, F. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.07.008 · Cited by 9
Metadata
- Authors
- Ma, H., Marti-Gutierrez, N., Park, S.-W., Wu, J., Lee, Y., Suzuki, K., Koski, A., Ji, D., Hayama, T., Ahmed, R., Darby, H., Van Dyken, C., Li, Y., Kang, E., Park, A.-R., Kim, D., Kim, S.-T., Gong, J., Gu, Y., Xu, X., Battaglia, D., Krieg, S. A., Lee, D. M., Wu, D. H., Wolf, D. P., Heitner, S. B., Belmonte, J. C. I., Amato, P., Kim, J.-S., Kaul, S., & Mitalipov, S.
- Affiliations
- Oregon Health & Science University (US)
- Institute for Basic Science (KR)
- Salk Institute for Biological Studies (US)
- Seoul National University (KR)
- BGI Group (China) (CN)
- Corresponding author
- Amato, Paula
- Kim, Jin-Soo
- Kaul, Sanjiv
- Mitalipov, Shoukhrat
- ORCID
- Venue
- Nature
- Published
- 2017-08
- Volume
- 548
- Issue
- 7668
- Pages
- 413-419
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2740810575
- Cited by
- 992
- References
- 48
- Citations by year
- 2026: 22 · 2025: 50 · 2024: 47 · 2023: 93 · 2022: 75 · 2021: 107 · 2020: 135 · 2019: 155 · 2018: 217 · 2017: 88
- Type
- journal article
- Language
- en
- Update notices
- expression_of_concern (2017-10-02)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Oregon Health and Science University
- Leona M. and Harry B. Helmsley Charitable Trust
- Consorzio Interuniversitario Biotecnologie
- Moxie Foundation
- Government of Jiangxi Province
- Institute for Basic Science (IBSR021-D1, R021-D1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Animal Genetics and Reproduction
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- germline editing, CRISPR/Cas9, MYBPC3 mutation, hypertrophic cardiomyopathy, preimplantation embryo, homology-directed repair, mosaicism, DNA double-strand break repair, cell cycle timing, preimplantation genetic diagnosis, off-target mutations
- MeSH terms
- Gene Editing, Myosin Binding Protein C, Adult, Alleles, Blastocyst, Carrier Proteins, Cell Division, Embryo, Mammalian, Genetic Complementation Test, Heterozygote, Homozygote, Humans, Male, Mosaicism, Mutation, Templates, Genetic, Zygote, S Phase, Gene Targeting, DNA Breaks, Double-Stranded, Recombinational DNA Repair, Clustered Regularly Interspaced Short Palindromic Repeats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.